GSE111061
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch Type Alopecia Areata, Totalis and Universalis
This study was an open-label, clinical trial to investigate tofacitinib 5 mg to 10 mg PO twice daily in the treatment of moderate/severe alopeica areata and to identify if gene expression of the scalp correlates with clinical response. Gene expression profiling was performed on scalp biopsies of alopecia areata patients taken at baseline and up to 24 weeks of treatment of tofacitinib. We applied both naïve and supervised clustering to this dataset in order to assess two features: the overall molecular effect of tofacitinib treatment on patient samples, and the concordant molecular response of the disease. The former was assessed by an unbiased, unsupervised differential expression analysis and the latter was measured by response to previously published gene expression signatures defining AA pathology. To ensure parity of the data, for this analysis we only included patient samples that had matched pre-treatment, Tx-00, and 24 weeks of treatment, Tx-24, samples. Gene expression profiles and Alopecia Areata Disease Activity Index (ALADIN) scores correlated with clinical response. Overall design: Gene expression analysis of 12 (6 T0 and 6 T24) scalp biopsies of alopecia areata patients and 6 control samples.